These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 12540064)

  • 1. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.
    Aggarwal R; Ghoshal UC; Naik SR
    Natl Med J India; 2002; 15(6):320-7. PubMed ID: 12540064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal.
    Dusheiko GM; Roberts JA
    Hepatology; 1995 Dec; 22(6):1863-73. PubMed ID: 7489999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
    Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
    Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha.
    Desai HG
    Natl Med J India; 2003; 16(3):175; author reply 175-6. PubMed ID: 12929870
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha.
    Babu S
    Natl Med J India; 2003; 16(3):175; author reply 175-6. PubMed ID: 12929872
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha.
    Nagral A
    Natl Med J India; 2003; 16(3):175; author reply 175-6. PubMed ID: 12929871
    [No Abstract]   [Full Text] [Related]  

  • 7. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States.
    Brooks EA; Lacey LF; Payne SL; Miller DW
    Am J Manag Care; 2001 Jul; 7(7):677-82. PubMed ID: 11464426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha].
    Buti M; Casado MA; Fosbrook L; Esteban R
    Gastroenterol Hepatol; 1998 Apr; 21(4):161-8. PubMed ID: 9633175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
    Veldhuijzen IK; Toy M; Hahné SJ; De Wit GA; Schalm SW; de Man RA; Richardus JH
    Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global cost-effectiveness of cataract surgery.
    Lansingh VC; Carter MJ; Martens M
    Ophthalmology; 2007 Sep; 114(9):1670-8. PubMed ID: 17383730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C.
    Shiell A; Briggs A; Farrell GC
    Med J Aust; 1994 Mar; 160(5):268-72. PubMed ID: 8107627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?
    Sheerin IG; Green FT; Sellman JD
    Drug Alcohol Rev; 2004 Sep; 23(3):261-72. PubMed ID: 15370005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial.
    Karabay O; Tamer A; Tahtaci M; Vardi S; Celebi H
    J Microbiol Immunol Infect; 2005 Aug; 38(4):262-6. PubMed ID: 16118673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients?
    Saab S; Ly D; Han SB; Lin RK; Rojter SE; Ghobrial RM; Busuttil RW
    Liver Transpl; 2002 May; 8(5):449-57. PubMed ID: 12004345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic consequences of HIV/AIDS in India.
    Pandav CS; Anand K; Shamanna BR; Chowdhury S; Nath LM
    Natl Med J India; 1997; 10(1):27-30. PubMed ID: 9069706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
    Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-effectiveness analysis of the treatment of chronic hepatitis C].
    Joliot E; Vanlemmens C; Kerleau M; Le Gales C; Woronoff-Lemsi MC; Flori YA; Seror V; Hrusovsky S; Monnet E; Bresson-Hadni S; Miguet JP
    Gastroenterol Clin Biol; 1996; 20(11):958-67. PubMed ID: 9119185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    Rothberg MB; Rose DN
    Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
    Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
    Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.